Search results
Stanley CROOKE, CEO | Cited by 28,750 | of Ionis Pharmaceuticals, Carlsbad | Read 576 publications | Contact Stanley CROOKE
Nine single-stranded antisense oligonucleotide (ASO) drugs representing four chemical classes, two mechanisms of action and four routes of administration have been approved for commercial use, including the first RNA-targeted drug to be a major commercial success, nusinersen.
Jun 6, 2019 · Stanley T. Crooke. Produced by. As scientists, our focus is on creating a different future. Because we are engaged in the discovery and development of new medicines, we have the extraordinary...
Dr. Stanley Crooke is founder, chairman and chief executive officer of n-Lorem, a…. · Experience: n-Lorem Foundation · Education: Baylor College of Medicine · Location: Carlsbad · 500 ...
May 11, 2023 · Stanley T. Crooke. Nature Medicine 29 , 1302–1303 ( 2023) Cite this article. 2066 Accesses. 7 Citations. 39 Altmetric. Metrics.
Sep 8, 2022 · More than 30 years ago, Dr. Stanley Crooke founded Ionis Pharmaceuticals — a biotech company that helped pioneer the now successful technology of antisense oligonucleotides (ASO) despite overwhelming challenges and widespread disbelief.
Dec 17, 2020 · Crooke will continue to serve as a scientific advisor to Ionis including providing advice regarding Ionis' research and development programs and guiding the core antisense research group he ...
